SB 875 Allows a pharmacist to select an interchangeable biological product when filling a biological product prescription
Sponsor: Schaefer
LR Number: 5452S.02T Fiscal Notes
Committee: Veterans' Affairs and Health
Last Action: 6/8/2016 - Signed by Governor Journal Page: S2325-2326
Title: Calendar Position:
Effective Date: August 28, 2016
House Handler: Hubrecht

Full Bill Text | All Actions | Amendments/CCRs/CCSs | Available Summaries | Senate Home Page | List of 2016 Senate Bills

Current Bill Summary


SB 875 - This act allows a pharmacist filling a prescription order for a brand name biological product to select a less expensive interchangeable biological product if the substitute has been approved by the FDA to be an interchangeable biological product, the prescriber has communicated that a interchangeable biological product may be substituted, and the pharmacist informs the patient. Within five days of dispensing a biological product, the pharmacist shall communicate the name and manufacturer of the product to the prescriber, unless there is no FDA approved interchangeable biological product or a refill prescription is not changed from the product dispensed on the prior filling.

The Board of Pharmacy shall maintain a link on its website to a current list of all biological products determined by the FDA to be interchangeable with a specific biological product.

This act is identical to SCS/HCS/HBs 1366 & 1878 (2016).

JESSI BAKER